Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 18/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 1/20 | 0.53 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.53 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159258 | 1.00 | ERN1 (1.00) | ERN1LMNAMAPTIGF1RTLR2 | |
| SCHEMBL15331811 | 0.83 | ERN1 (0.71) | ERN1LMNAMAPTIGF1R | |
| SCHEMBL15331813 | 0.83 | ERN1 (0.71) | ERN1LMNAMAPTIGF1R | |
| SCHEMBL16475647 | 0.81 | ERN1 (0.68) | ERN1LMNAMAPTIGF1RTLR2 | |
| SCHEMBL11052763 | 0.81 | ERN1 (0.70) | ERN1LMNAMAPTTLR2TLR1 | |
| SCHEMBL1620544 | 0.81 | ERN1 (0.68) | ERN1LMNAMAPTIGF1R | |
| SCHEMBL544809 | 0.80 | ERN1 (0.78) | ERN1 | |
| SCHEMBL1879373 | 0.80 | ERN1 (0.64) | ERN1LMNAMAPT | |
| SCHEMBL8679776 | 0.79 | ERN1 (0.68) | ERN1LMNAMAPTTLR2TLR1 | |
| SCHEMBL881403 | 0.79 | ERN1 (1.00) | ERN1LMNAMAPTTLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563163-A | Synthetic method of 5-bromo-1, 2, 3-trimethoxybenzene | 南京伊派森化学科技有限公司 | 2021-10-29 | — | — | CN | claimed |
| CN-108440577-B | Mixed copper-based complex and preparation method and application thereof | 桂林医学院 | 2020-05-12 | — | — | CN | claimed |
| CN-105601561-B | Piperidones Schiff base derivatives of 3,5 2 aryl methylene 4 with antitumor activity and preparation method thereof | 滨州医学院 | 2018-04-10 | — | — | CN | claimed |
| CN-105601561-A | 3,5-diaryl methylene-4-piperidone Schiff base derivatives with antitumor activity and preparing method thereof | BINZHOU MEDICAL COLLEGE | 2016-05-25 | — | — | CN | claimed |
| CN-104130160-A | Acylhydrazone compound containing aromatic ring and preparation method thereof | UNIV XI AN SCI & TECHNOLOGY | 2014-11-05 | — | — | CN | claimed |
| US-20060084176-A1 | Detection of uronium salts | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-04-20 | — | — | US | claimed |
| US-6797745-B1 | Hot melt inks containing styrene or terpene polymers | XEROX CORPORATION | 2004-09-28 | — | — | US | claimed |
| US-6780900-B1 | ALDEHYDE COPOLYMER INK VEHICLE, A NONPOLYMERIC ALDEHYDE VISCOSITY MODIFIER, COLORANT, AN OPTIONAL CONDUCTIVITY ENHANCING AGENT, AN OPTIONAL ANTIOXIDANT, AND AN OPTIONAL UV ABSORBER | XEROX CORPORATION | 2004-08-24 | — | — | US | claimed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20250231180-A1 | FLUORESCENT TURN-ON CHEMOSENSORS FOR DETECTION OF ALUMINUM ION AND AZIDE | MORGAN STATE UNIVERSITY | 2025-07-17 | — | — | US | disclosed |
| US-20250231180-A1 | FLUORESCENT TURN-ON CHEMOSENSORS FOR DETECTION OF ALUMINUM ION AND AZIDE | MORGAN STATE UNIVERSITY | 2025-07-17 | — | — | US | disclosed |
| WO-2025124544-A1 | 3,4-DIHYDRO-2H-BENZO[B][1,4]DIOXEPANE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 华润医药研究院（深圳）有限公司 | 2025-06-19 | — | — | WO | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| US-5620991-A | ANTICOAGULANTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| WO-1996040108-A1 | MULTIDENTATE METAL COMPLEXES AND METHODS OF MAKING AND USING THEREOF | WASHINGTON UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5576343-A | ANTICOAGULANTS; BLOOD-COAGULATION FACTOR X INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0540051-B1 | Aromatic amidine derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1996-04-03 | — | — | EP | disclosed |
| EP-0540051-A1 | Aromatic amidine derivatives and salts thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0103173-A1 | Carbamic-acid esters, process and starting material for their preparation, parasiticides containing these esters as active products, as well as the use of such esters and agents in combating parasites | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | ERN1 3303/4885LMNA 1698/4885MAPT 4793/4885 |
| US-20250231180-A1 | FLUORESCENT TURN-ON CHEMOSENSORS FOR DETECTION OF ALUMINUM ION AND AZIDE | MYBBP1A, MYB, NCS1 | ERN1 2902/4885LMNA 274/4885MAPT 3684/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | ERN1 2603/4885LMNA 4848/4885MAPT 1811/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | ERN1 1832/4885LMNA 1844/4885MAPT 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.